Harvard Bioscience (HBIO) Current Leases (2019 - 2026)

Harvard Bioscience (HBIO) has 8 years of Current Leases data on file, last reported at $1.6 million in Q1 2026.

• On a quarterly basis, Current Leases rose 9.37% year-over-year to $1.6 million in Q1 2026; TTM through Mar 2026 was $1.6 million, a 9.37% increase from a year earlier, with the FY2025 full-year figure at $1.5 million, up 31.69% from the prior year.
• Current Leases for Q1 2026 stood at $1.6 million, up from $1.5 million in the prior quarter.
• Over the last five years, Current Leases for HBIO reached as high as $2.2 million in Q1 2022 and fell as low as $1.1 million in Q2 2024.
• Historically, Current Leases has averaged $1.7 million across 5 years, with a median of $1.5 million in 2025.
• Across the five-year window, Current Leases sank 50.21% in 2024 and soared 37.33% in 2025, its largest moves.
• Year by year, Current Leases stood at $2.1 million in 2022, then slumped by 33.68% to $1.4 million in 2023, then decreased by 18.22% to $1.2 million in 2024, then surged by 31.69% to $1.5 million in 2025, then rose by 1.77% to $1.6 million in 2026.
• Per Business Quant data, the three most recent Current Leases figures were $1.6 million in Q1 2026, $1.5 million in Q4 2025, and $1.5 million in Q3 2025.